Rifampicin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Rifampicin

---

CLASS

Rifamycin

---

TARGET PROTEIN

RNA synthesis through interfering with bacterial RNA-polymerase

---

MECHANISM OF ACTION

Bactericidal activity (act on mycobacteria by inhibiting RNA synthesis through interfering with bacterial RNA-polymerase)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Approved

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/ 

https://pubmed.ncbi.nlm.nih.gov/24396561/

https://pubmed.ncbi.nlm.nih.gov/30136733/

---

SIMILAR TARGETS IN OTHER SPECIES

DNA-directed RNA polymerase subunit beta ~ Escherichia coli (strain K12)

---

DRUG BANK ID

DB01045

---

EXTERNAL LINKS

Human Metabolome Database HMDB15179

KEGG Drug D00211

KEGG Compound C06688

PubChem Compound 5381226

PubChem Substance 46506170

ChemSpider 10468813

BindingDB 50370232

RxNav 9384


ChEBI 71365


ChEMBL CHEMBL374478

ZINC ZINC000169621223

Guide to Pharmacology GtP Drug Page



Drugs.com Drugs.com Drug Page  https://www.drugs.com/cdi/rifampin.htm

Wikipedia Rifampicin

---

REFERENCE

Vouking, M. Z., Tamo, V. C., & Tadenfok, C. N. (2013). Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: A systematic review. In Pan African Medical Journal (Vol. 15). Pan Afr Med J. https://doi.org/10.11604/pamj.2013.15.155.2341



Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4



Yotsu, R. R., Richardson, M., & Ishii, N. (2018). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews, 2018(8). https://doi.org/10.1002/14651858.CD012118.pub2



Organization, W. H. (2022). WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01659437

---